1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Preventive Vaccines
3.2.1. Classification of Vaccines
3.2.1.1. Live, Attenuated Vaccines
3.2.1.2. Inactivated Vaccines
3.2.1.3. Subunit Vaccines
3.2.1.4. Toxoid Vaccines
3.2.1.5. DNA Vaccines
3.2.2. Key Components of a Vaccine Formulation
3.2.3. Production of Vaccines using Different Expression Systems
3.2.3.1. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
3.2.3.2. Mammalian Expression Systems
3.2.3.3. Avian Expression Systems
3.2.3.4. Plant Expression Systems
3.2.3.5. Bacterial Expression Systems
3.2.3.6. Yeast Expression Systems
3.2.3.7. Insect Expression System
3.2.4. Routes of Vaccine Administration
3.2.4.1. Intramuscular Route
3.2.4.2. Subcutaneous Route
3.2.4.3. Oral Route
3.2.4.4. Intranasal Route
3.2.4.5. Intradermal Route
3.2.4.6. Inhalation
3.2.5. Clinical Development and Approval of Vaccines
3.2.6. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Preventive Vaccines: Overall Market Landscape
4.2.1. Marketed Vaccines Landscape
4.2.2. Clinical-Stage Vaccines Landscape
4.2.2.1. Analysis by Type of Developer
4.2.2.2. Analysis by Phase of Development
4.2.2.3. Analysis by Route of Administration
4.2.2.4. Analysis by Type of Vaccine API
4.2.2.5. Analysis by Dosage Form
4.2.2.6. Analysis by Dosage
4.2.2.7. Analysis by Target Disease Indication
4.2.2.8. Analysis by Target Patient Population
4.2.2.9. Key Industry Players: Analysis by Number of Vaccines in Clinical Development
4.2.2.10. Key Non-Industry Players: Analysis by Number of Vaccines in Clinical Development

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Parameters
5.4. Competitiveness Analysis: Preventive Vaccine Developers
5.4.1. Preventive Vaccine Developers based in North America
5.4.2. Preventive Vaccine Developers based in Europe
5.4.3. Preventive Vaccine Developers based in Asia Pacific

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Bio Farma
6.2.1. Company Overview
6.2.2. Preventive Vaccines Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Emergent BioSolutions
6.3.1. Company Overview
6.3.2. Preventive Vaccines Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. GC Pharma
6.4.1. Company Overview
6.4.2. Preventive Vaccines Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. GlaxoSmithKline
6.5.1. Company Overview
6.5.2. Preventive Vaccines Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Janssen
6.6.1. Company Overview
6.6.2. Preventive Vaccines Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Merck
6.7.1. Company Overview
6.7.2. Preventive Vaccines Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Novavax
6.8.1. Company Overview
6.8.2. Preventive Vaccines Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Pfizer
6.9.1. Company Overview
6.9.2. Preventive Vaccines Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Sanofi Pasteur
6.10.1. Company Overview
6.10.2. Preventive Vaccines Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. Valneva
6.11.1. Company Overview
6.11.2. Preventive Vaccines Portfolio
6.11.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Preventive Vaccines: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Enrolled Patient Population and Trial Registration Year
7.3.3. Analysis by Trial Phase
7.3.4. Analysis by Trial Recruitment Status
7.3.5. Analysis by Study Design
7.3.6. Analysis by Trial Focus Area
7.3.7. Analysis by Type of Preventive Vaccine (based on Pathogen)
7.3.8. Analysis by Target Disease Indication
7.3.9. Analysis by Type of Sponsor / Collaborator
7.3.10. Leading Industry Players: Analysis by Number of Registered Trials
7.3.11. Geographical Analysis by Number of Registered Trials
7.3.12. Geographical Analysis by Enrolled Patient Population
7.3.13. Geographical Analysis by Trial Recruitment Status

8. ONGOING VACCINE DEVELOPMENT INITIATIVES FOR COMPLEX CONDITIONS
8.1. Chapter Overview
8.2. Coronavirus Disease (COVID-19)
8.2.1. Disease Overview
8.2.2. Global Burden of COVID-19
8.2.3. Current Treatment Landscape
8.2.4. Preventive Vaccines for COVID-19
8.2.4.1. Historical Background of COVID-19 Vaccine Research
8.2.4.2. COVID-19 and Affiliated Research Landscape
8.2.5. Funding Instances
8.2.6. Recent Developments
8.3. Ebola Virus Disease (EVD)
8.3.1. Disease Overview
8.3.2. Global Burden of EVD
8.3.3. Current Treatment Landscape
8.3.4. Preventive Vaccines for EVD
8.3.4.1. Historical Background of Ebola Virus Vaccine Research
8.3.4.2. Anti-Ebola Virus Vaccines and Affiliated Research Landscape
8.3.5. Funding Instances
8.3.6. Recent Developments
8.4. HIV/AIDS
8.4.1. Disease Overview
8.4.2. Global Burden of HIV/AIDS
8.4.3. Current Treatment Landscape
8.4.4. Preventive Vaccines for HIV/AIDS
8.4.4.1. Historical Background of HIV/AIDS Vaccine Research
8.4.4.2. Anti-HIV Vaccines and Affiliated Research Landscape
8.4.5. Funding Instances
8.4.6. Recent Developments
8.5. Malaria
8.5.1. Disease Overview
8.5.2. Global Burden of Malaria
8.5.3. Current Treatment Landscape
8.5.4. Preventive Vaccines for Malaria
8.5.4.1. Historical Background of Malaria Vaccine Research
8.5.4.2. Anti-Malaria Vaccines and Affiliated Research Landscape
8.5.5. Funding Instances
8.5.6. Recent Developments
8.6. Zika Virus Infection
8.6.1. Disease Overview
8.6.2. Global Burden of Zika Virus Infection
8.6.3. Current Treatment Landscape
8.6.4. Preventive Vaccines for Zika Virus Infection
8.6.4.1. Historical Background of Zika Virus Vaccine Research
8.6.4.2. Anti-Zika Virus Vaccines and Affiliated Research Landscape
8.6.5. Funding Instances
8.6.6. Recent Developments

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Preventive Vaccines: Funding and Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Amount Invested across Different Types of Vaccine API
9.3.5. Analysis by Focus Area
9.3.6. Analysis by Amount Invested by Different Type of Investors
9.3.7. Most Active Players: Analysis by Number of Funding Instances
9.3.8. Most Active Investors: Analysis by Number of Funding Instances
9.3.9. Analysis by Geography
9.3.9.1. Continent-wise Analysis
9.3.9.2. Country-wise Analysis

10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall Preventive Vaccines Market, 2020-2030
10.3.1. Preventive Vaccines Market, 2020-2030: Distribution by Route of Administration
10.3.2. Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine
10.3.3. Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine API
10.3.4. Preventive Vaccines Market, 2020-2030: Distribution by Target Patient Population
10.3.5. Preventive Vaccines Market, 2020-2030: Distribution by Key Geographical Regions
10.3.5.1. Preventive Vaccines Market in North America, 2020-2030
10.3.5.1.1. Preventive Vaccines Market in the US, 2020-2030
10.3.5.1.2. Preventive Vaccines Market in Mexico, 2020-2030
10.3.5.1.2. Preventive Vaccines Market in Canada, 2020-2030
10.3.5.2. Preventive Vaccines Market in Europe, 2020-2030
10.3.5.2.1. Preventive Vaccines Market in Spain, 2020-2030
10.3.5.2.2. Preventive Vaccines Market in the UK, 2020-2030
10.3.5.2.3. Preventive Vaccines Market in Italy, 2020-2030
10.3.5.2.4. Preventive Vaccines Market in France, 2020-2030
10.3.5.2.5. Preventive Vaccines Market in Germany, 2020-2030
10.3.5.2.6. Preventive Vaccines Market in Rest of Europe, 2020-2030
10.3.5.3. Preventive Vaccines Market in Asia Pacific, 2020-2030
10.3.5.3.1. Preventive Vaccines Market in India, 2020-2030
10.3.5.3.2. Preventive Vaccines Market in China, 2020-2030
10.3.5.3.3. Preventive Vaccines Market in Australia, 2020-2030
10.3.5.3.4. Preventive Vaccines Market in Rest of Asia Pacific, 2020-2030
10.3.5.4. Preventive Vaccines Market in Rest of the World, 2020-2030
 
11. CASE-IN-POINT: CONTRACT MANUFACTURING OF VACCINES
11.1. Chapter Overview
11.2. Vaccine Contract Manufacturing
11.2.1. Addressing an Unmet Need
11.2.2. Commonly Outsourced Operations
11.2.3. Selecting a CMO Partner
11.2.4. Advantages of Outsourcing Manufacturing Services
11.2.5. Associated Risks and Challenges
11.3. Vaccine Contract Manufacturing: Overall Market Landscape
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Scale of Operation
11.3.4. Analysis by Location of Headquarters
11.3.5. Analysis by Location of Manufacturing Facilities
11.3.6. Analysis by Type of Service(s) Offered
11.3.7. Analysis by Expression System Used
11.3.8. Analysis by Type of Vaccine Manufactured
11.3.9. Analysis by Type of Vaccine Manufactured and Location of Headquarters

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Alopexx
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Daniel R. Vlock, Chief Executive Officer

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Difference Between Vaccines and Small Molecules
Figure 3.2 Classification of Vaccines
Figure 3.3 Routes for Vaccine Administration
Figure 4.1 Clinical-Stage Preventive Vaccines: Distribution by Type of Developer
Figure 4.2 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
Figure 4.3 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
Figure 4.4 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
Figure 4.5 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
Figure 4.6 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
Figure 4.7 Clinical-Stage Preventive Vaccines: Distribution by Dosage
Figure 4.8 Clinical-Stage Preventive Vaccines: Distribution by Target Disease Indication
Figure 4.9 Clinical-Stage Preventive Vaccines: Distribution by Target Patient Population
Figure 4.10 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
Figure 4.11 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
Figure 5.1 Company Competitiveness Analysis: Preventive Vaccine Developers based in North America
Figure 5.2 Company Competitiveness Analysis: Preventive Vaccine Developers based in Europe
Figure 5.3 Company Competitiveness Analysis: Preventive Vaccine Developers based in Asia Pacific
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2020
Figure 7.3 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Pre-2010-2020
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 7.6 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 7.7 Clinical Trial Analysis: Distribution by Study Design
Figure 7.8 Clinical Trial Analysis: Distribution by Trial Focus Area
Figure 7.9 Clinical Trial Analysis: Distribution by Type of Preventive Vaccine (based on Pathogen)
Figure 7.10 Clinical Trial Analysis: Cumulative Year-wise Trend by Type of Preventive Vaccines
Figure 7.11 Clinical Trial Analysis: Distribution by Target Disease Indication
Figure 7.12 Clinical Trial Analysis: Distribution by Patient Enrollment and Target Disease Indication
Figure 7.13 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.14 Leading Industry Players: Distribution by Number of Registered Trials
Figure 7.15 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 7.16 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.17 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Figure 8.1 Historical Timeline of COVID-19 Vaccine Development
Figure 8.2 Historical Timeline of Anti-Ebola Virus Vaccine Development
Figure 8.3 Historical Timeline of Anti-HIV Vaccine Development
Figure 8.4 Historical Timeline of Anti-Malaria Vaccine Development
Figure 8.5 Historical Timeline of Anti-Zika Virus Vaccine Development
Figure 9.1 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2015-Q1 2020
Figure 9.2 Funding and Investment Analysis: Cumulative Amount Invested, 2015-Q1 2020 (USD Million)
Figure 9.3 Funding and Investment Analysis: Distribution by Type of Funding, 2015-Q1 2020
Figure 9.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2015-Q1 2020 (USD Million)
Figure 9.5 Funding and Investment Analysis: Distribution of Amount Invested by Type of Vaccine API
Figure 9.6 Funding and Investment Analysis: Distribution of Amount Invested and Focus Area
Figure 9.7 Funding and Investment Analysis: Distribution of Amount Invested by Different Type of Investors
Figure 9.8 Most Active Players: Distribution by Number of Funding Instances
Figure 9.9 Most Active Investors: Distribution by Number of Funding Instances
Figure 9.10 Funding and Investment Analysis: Regional Distribution by Number of Funding Instances and Amount Raised (USD Million)
Figure 9.11 Funding and Investment Analysis: Country-wise Distribution by Total Amount Invested (USD Million)
Figure 10.1 Overall Preventive Vaccines Market, 2020-2030 (USD Billion)
Figure 10.2 Preventive Vaccines Market, 2020-2030: Distribution by Route of Administration (USD Billion)
Figure 10.3 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine (USD Billion)
Figure 10.4 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine API (USD Billion)
Figure 10.5 Preventive Vaccines Market, 2020-2030: Distribution by Target Patient Population (USD Billion)
Figure 10.6 Preventive Vaccines Market, 2020-2030: Distribution by Key Geographical Regions (USD Billion)
Figure 10.7 Preventive Vaccines Market in North America, 2020-2030 (USD Billion)
Figure 10.8 Preventive Vaccines Market in the US, 2020-2030 (USD Billion)
Figure 10.9 Preventive Vaccines Market in Mexico, 2020-2030 (USD Billion)
Figure 10.10 Preventive Vaccines Market in Canada, 2020-2030 (USD Billion)
Figure 10.11 Preventive Vaccines Market in Europe, 2020-2030 (USD Billion)
Figure 10.12 Preventive Vaccines Market in Spain, 2020-2030 (USD Billion)
Figure 10.13 Preventive Vaccines Market in the UK, 2020-2030 (USD Billion)
Figure 10.14 Preventive Vaccines Market in Italy, 2020-2030 (USD Billion)
Figure 10.15 Preventive Vaccines Market in France, 2020-2030 (USD Billion)
Figure 10.16 Preventive Vaccines Market in Germany, 2020-2030 (USD Billion)
Figure 10.17 Preventive Vaccines Market in Rest of Europe, 2020-2030 (USD Billion)
Figure 10.18 Preventive Vaccines Market in Asia Pacific, 2020-2030 (USD Billion)
Figure 10.19 Preventive Vaccines Market in India, 2020-2030 (USD Billion)
Figure 10.20 Preventive Vaccines Market in China, 2020-2030 (USD Billion)
Figure 10.21 Preventive Vaccines Market in Australia, 2020-2030 (USD Billion)
Figure 10.22 Preventive Vaccines Market in Rest of Asia Pacific, 2020-2030 (USD Billion)
Figure 10.23 Preventive Vaccines Market in Rest of the World, 2020-2030 (USD Billion)
Figure 11.1 Type of Third-Party Service Providers in the Pharmaceutical Industry
Figure 11.2 Commonly Outsourced Vaccine Development Operations
Figure 11.3 Key Factors to Consider while Selecting a CMO Partner
Figure 11.4 Risks and Challenges Associated with Contract Manufacturing
Figure 11.5 Vaccine CMOs: Distribution by Year of Establishment
Figure 11.6 Vaccine CMOs: Distribution by Company Size
Figure 11.7 Vaccine CMOs: Distribution by Scale of Operation
Figure 11.8 Vaccine CMOs: Distribution by Location of Headquarters (Region and Country-wise)
Figure 11.9 Vaccine CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
Figure 11.10 Vaccine CMOs: Distribution by Type of Services Offered
Figure 11.11 Vaccine CMOs: Distribution by Expression System Used
Figure 11.12 Vaccine CMOs: Distribution by Type of Vaccine Manufactured
Figure 11.13 Vaccine CMOs: Distribution by Type of Vaccine Manufactured and Location of Headquarters

List Of Tables

Table 3.1 Classification of Vaccines
Table 3.2 Live, Attenuated Vaccines: Commonly Reported Adverse Events
Table 3.3 Inactivated Vaccines: Commonly Reported Adverse Events
Table 3.4 Subunit Vaccines: Commonly Reported Adverse Events
Table 3.5 Toxoid Vaccines: Commonly Reported Adverse Events
Table 3.6 Vaccine Excipients and their Functions
Table 3.7 Routes of Administration and Type of Delivery Devices for Vaccine Administration
Table 3.8 Common Pediatric Vaccines and their Routes of Administration
Table 4.1 List of Marketed Preventive Vaccines
Table 4.2 List of Clinical-Stage Preventive Vaccines
Table 6.1 Preventive Vaccine Developers: List of Companies Profiled
Table 6.2 Bio Farma: Company Overview
Table 6.3 Bio Farma: Preventive Vaccine Pipeline
Table 6.4 Bio Farma: Recent Developments and Future Outlook
Table 6.5 Emergent BioSolutions: Company Overview
Table 6.6 Emergent BioSolutions: Preventive Vaccine Pipeline
Table 6.7 Emergent BioSolutions: Recent Developments and Future Outlook
Table 6.8 GC Pharma: Company Overview
Table 6.9 GC Pharma: Preventive Vaccine Pipeline
Table 6.10 GC Pharma: Recent Developments and Future Outlook
Table 6.11 GlaxoSmithKline: Company Overview
Table 6.12 GlaxoSmithKline: Preventive Vaccine Pipeline
Table 6.13 GlaxoSmithKline: Recent Developments and Future Outlook
Table 6.14 Janssen: Company Overview
Table 6.15 Janssen: Preventive Vaccine Pipeline
Table 6.16 Janssen: Recent Developments and Future Outlook
Table 6.17 Merck: Company Overview
Table 6.18 Merck: Preventive Vaccine Pipeline
Table 6.19 Merck: Recent Developments and Future Outlook
Table 6.20 Novavax: Company Overview
Table 6.21 Novavax: Preventive Vaccine Pipeline
Table 6.22 Novavax: Recent Developments and Future Outlook
Table 6.23 Pfizer: Company Overview
Table 6.24 Pfizer: Preventive Vaccine Pipeline
Table 6.25 Pfizer: Recent Developments and Future Outlook
Table 6.26 Sanofi Pasteur: Company Overview
Table 6.27 Sanofi Pasteur: Preventive Vaccine Pipeline
Table 6.28 Sanofi Pasteur: Recent Developments and Future Outlook
Table 6.29 Valneva: Company Overview
Table 6.30 Valneva: Preventive Vaccine Pipeline
Table 6.31 Valneva: Recent Developments and Future Outlook
Table 8.1 Preventive Vaccines under Investigation for COVID-19
Table 8.2 COVID-19 Vaccines: Funding Instances
Table 8.3 Ebola Virus Disease: List of Marketed Therapeutics
Table 8.4 Preventive Vaccines under Investigation for Ebola Virus Disease
Table 8.5 Anti-Ebola Virus Vaccines: Funding Instances
Table 8.6 HIV/AIDS: List of Marketed Therapeutics
Table 8.7 Preventive Vaccines under Investigation for HIV/AIDS
Table 8.8 Anti-HIV Vaccines: Funding Instances
Table 8.9 Malaria: List of Marketed Therapeutics
Table 8.10 Preventive Vaccines under Investigation for Malaria
Table 8.11 Anti-Malaria Vaccines: Funding Instances
Table 8.12 Preventive Vaccines under Investigation for Zika Virus Infection
Table 8.13 Anti-Zika Virus Vaccines: Funding Instances
Table 9.1 Preventive Vaccines: List of Funding and Investments, till Q1 2020
Table 11.1 Vaccine Contract Manufacturers: List of Service Providers
Table 11.2 Vaccine CMOs: Information on Type of Services Offered
Table 11.3 Vaccine CMOs: Information on Scale of Operation
Table 11.4 Vaccine CMOs: Information on Expression System Used
Table 11.5 Vaccine CMOs: Information on Type of Vaccines Manufactured
Table 11.6 List of Ad hoc Vaccine Manufacturers
Table 12.1 Preventive Vaccines Market: Summary of the Report
Table 14.1 Clinical-Stage Preventive Vaccines: Distribution by Type of Developer
Table 14.2 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
Table 14.3 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
Table 14.4 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
Table 14.5 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
Table 14.6 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
Table 14.7 Clinical-Stage Preventive Vaccines: Distribution by Dosage
Table 14.8 Clinical-Stage Preventive Vaccines: Distribution by Target Disease Indication
Table 14.9 Clinical-Stage Preventive Vaccines: Distribution by Target Patient Population
Table 14.10 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
Table 14.11 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
Table 14.12 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2020
Table 14.13 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Pre-2010-2020
Table 14.14 Clinical Trial Analysis: Distribution by Trial Phase
Table 14.15 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 14.16 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Table 14.17 Clinical Trial Analysis: Distribution by Study Design
Table 14.18 Clinical Trial Analysis: Distribution by Trial Focus Area
Table 14.19 Clinical Trial Analysis: Distribution by Type of Preventive Vaccine (based on Pathogen)
Table 14.20 Clinical Trial Analysis: Cumulative Year-wise Trend by Type of Preventive Vaccines
Table 14.21 Clinical Trial Analysis: Distribution by Target Disease Indication
Table 14.22 Clinical Trial Analysis: Distribution by Patient Enrollment and Target Disease Indication
Table 14.23 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 14.24 Leading Industry Players: Distribution by Number of Registered Trials
Table 14.25 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2015-Q1 2020
Table 14.26 Funding and Investment Analysis: Cumulative Amount Invested, 2015-Q1 2020 (USD Million)
Table 14.27 Funding and Investment Analysis: Distribution by Type of Funding, 2015-Q1 2020
Table 14.28 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2015-Q1 2020 (USD Million)
Table 14.29 Funding and Investment Analysis: Distribution of Amount Invested by Type of Vaccine API
Table 14.30 Funding and Investment Analysis: Distribution of Amount Invested by Focus Area
Table 14.31 Funding and Investment Analysis: Distribution of Amount Invested by Different Type of Investors
Table 14.32 Most Active Players: Distribution by Number of Funding Instances
Table 14.33 Most Active Investors: Distribution by Number of Funding Instances
Table 14.34 Funding and Investment Analysis: Regional Distribution by Number of Funding Instances and Amount Raised (USD Million)
Table 14.35 Funding and Investment Analysis: Country-wise Distribution by Total Amount Invested (USD Million)
Table 14.36 Overall Preventive Vaccines Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.37 Preventive Vaccines Market, 2020-2030: Distribution by Route of Administration (USD Billion)
Table 14.38 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine (USD Billion)
Table 14.39 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine API (USD Billion)
Table 14.40 Preventive Vaccines Market, 2020-2030: Distribution by Target Patient Population (USD Billion)
Table 14.41 Preventive Vaccines Market, 2020-2030: Distribution by Key Geographical Regions (USD Billion)
Table 14.42 Preventive Vaccines Market in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.43 Preventive Vaccines Market in the US, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.44 Preventive Vaccines Market in Mexico, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.45 Preventive Vaccines Market in Canada, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.46 Preventive Vaccines Market in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.47 Preventive Vaccines Market in Spain, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.48 Preventive Vaccines Market in the UK, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.49 Preventive Vaccines Market in Italy, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.50 Preventive Vaccines Market in France, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.51 Preventive Vaccines Market in Germany, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.52 Preventive Vaccines Market in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.53 Preventive Vaccines Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.54 Preventive Vaccines Market in India, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.55 Preventive Vaccines Market in China, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.56 Preventive Vaccines Market in Australia, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.57 Preventive Vaccines Market in Rest of Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.58 Preventive Vaccines Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
Table 14.59 Vaccine CMOs: Distribution by Year of Establishment
Table 14.60 Vaccine CMOs: Distribution by Company Size
Table 14.61 Vaccine CMOs: Distribution by Scale of Operation
Table 14.62 Vaccine CMOs: Distribution by Location of Headquarters (Region and Country-wise)
Table 14.63 Vaccine CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
Table 14.64 Vaccine CMOs: Distribution by Type of Services Offered
Table 14.65 Vaccine CMOs: Distribution by Expression System Used
Table 14.66 Vaccine CMOs: Distribution by Type of Vaccines Manufactured
Table 14.67 Vaccine CMOs: Region-wise Distribution by Type of Vaccine Manufactured

Title: Global Preventive Vaccines Market, 2020-2030

The ‘Global Preventive Vaccines Market, 2020-2030’ report features an extensive study of the current market landscape and future opportunities associated with the preventive vaccine domain. The study also features a detailed analysis of the key drivers and trends related to this evolving segment of the pharmaceutical industry. Amongst other elements, the report includes:

• A detailed assessment of the current market landscape, including information on type of developer (industry, non-industry, industry / non-industry), phase of development (phase I, phase I/II, phase II, phase II/III, phase III and preregistration) of lead candidates, route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others), type of vaccine API (live, attenuated vaccine, recombinant vaccine, conjugate vaccine, inactivated vaccine, DNA vaccine, peptide vaccine, subunit vaccine, mRNA vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule and tablet), dosage (single dose, 2 doses, 3 doses, 4 doses, 5 doses and 6 doses), target disease indication and target patient population (children, adults and seniors).
• A competitiveness analysis of preventive vaccine developers, taking into consideration supplier strength (based on company size and its experience in this field) and pipeline strength (based on the number of clinical-stage vaccine candidates, highest phase of development, number of compatible routes of administration, number of indications evaluated, number of APIs evaluated and target patient population).
• Elaborate profiles of the key preventive vaccine developers (shortlisted based on a proprietary criterion) across North America, Europe and Asia Pacific. Each profile includes a brief overview of the company, its year of establishment, location of headquarters, number of employees and financial information (if available). In addition to this, the profile includes information on the various clinical-stage vaccine candidates developed by the company. Further, we have provided the recent developments of the company and an informed future outlook.
• A detailed analysis of more than 1,400 completed, ongoing and planned clinical studies of preventive vaccines, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, trial recruitment status, study design, trial focus area, type of preventive vaccine (based on pathogen), target disease indication(s),  type of sponsor / collaborator, leading industry sponsors / collaborators (in terms of number of trials conducted), enrolled patients population and regional distribution.
• An overview of the ongoing vaccine development initiatives for complex conditions, such as COVID-19, ebola virus disease, HIV/AIDS, malaria and zika virus infection, including information on disease, its global burden, current treatment landscape and preventive vaccine research landscape. Further, we have provided the information on investments made and recent developments in the domain.
• An analysis of the investments made in this domain, during the period between 2015 and 2020 (till March), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in developing preventive vaccines. 
• A case study on contract manufacturing landscape for vaccines, featuring a comprehensive list of active CMOs and analyses based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), type of expression systems used for vaccine production (mammalian, microbial and others) and type of vaccine manufactured.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for preventive vaccines over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] route of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others), [B] type of vaccine (pneumococcal conjugate vaccine, human papilloma virus vaccine, influenza vaccine, rotavirus vaccine, varicella vaccine, DTP-HepB-Hib vaccine, meningococcal group A, C, Y and W-135 vaccine and others), [C] type of vaccine API (live attenuated vaccine, inactivated vaccine, conjugate vaccine, subunit vaccine, toxoid vaccine and others), [D] target patient population (pediatric and adults) and [E] key geographical regions, covering North America (the US, Mexico and Canada), Europe (Spain, the UK, Italy, France, Germany and rest of Europe), Asia Pacific (India, China, Australia and rest of Asia Pacific), and rest of the world. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.